FDA defines 510(k) fee schedule:
This article was originally published in Clinica
Hoping to clear up potential confusion, the US FDA says that with only limited exceptions all 510(k)s submitted for FDA review in fiscal year 2003 are subject to a standard fee of $2,187 for 2004 which begins next October, the agency said.
You may also be interested in...
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.
Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.